Celularity (NASDAQ:CELU) Posts Earnings Results

Celularity (NASDAQ:CELU) posted its quarterly earnings data on Thursday. The company reported ($0.85) EPS for the quarter, FiscalAI reports. The company had revenue of $4.10 million during the quarter.

Celularity Price Performance

Shares of Celularity stock traded up $0.02 during midday trading on Friday, reaching $0.96. The company had a trading volume of 1,447,615 shares, compared to its average volume of 33,334. Celularity has a fifty-two week low of $0.93 and a fifty-two week high of $4.35. The stock has a fifty day moving average price of $1.24 and a 200 day moving average price of $1.45. The firm has a market cap of $27.60 million, a PE ratio of -0.29 and a beta of 0.45.

Hedge Funds Weigh In On Celularity

Several institutional investors have recently added to or reduced their stakes in CELU. Acadian Asset Management LLC acquired a new position in Celularity in the first quarter valued at approximately $34,000. XTX Topco Ltd lifted its stake in Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after buying an additional 11,057 shares during the period. Bank of America Corp DE lifted its stake in Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after buying an additional 35,023 shares during the period. HB Wealth Management LLC acquired a new position in Celularity in the third quarter valued at approximately $84,000. Finally, Vanguard Group Inc. lifted its stake in Celularity by 35.3% in the third quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after buying an additional 176,518 shares during the period. 19.02% of the stock is owned by institutional investors and hedge funds.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.